Key References

Key References on Thrombolytic Therapy
1983-1993

Désiré Collen, MD, PhD; Marc Verstraete, MD

Periodically, Circulation will publish a list of references that are considered to be among the most important and informative in that field. These lists will be compiled by a Physician-Scientist who has made important contributions to the same topic. A previous editor of Circulation, Dr Burton Sobel, introduced this practice in Circulation, and we believe it is a valuable one.

Review Articles


Sherry S, Marder VJ. Thrombosis, fibrinolysis, and thrombolytic therapy: a perspective. Prog Cardiovasc Dis. 1991;34:89-100.


From the Center for Molecular and Vascular Biology, Leuven, Belgium.

Correspondence to D. Collen, MD, PhD, Center for Molecular and Vascular Biology, Campus Gasthuisberg, O & N, Herestraat 49, B-3000 Leuven, Belgium.
Thrombolysis in Acute Myocardial Infarction


Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombi-


Verstraete M. Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. *Eur Heart J.* 1985;6:586-593.


Williams DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knat-


ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither...


Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and hepa-


**Thrombolysis in Acute Pulmonary Embolism**


**Thrombolysis in Peripheral Arterial Occlusion**


Thrombolysis in Thrombotic Stroke


**Thrombolysis in Deep Vein Thrombosis**


